GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » 3-Year Book Growth Rate

Biomarin Pharmaceutical (LTS:0HNC) 3-Year Book Growth Rate

: 5.10% (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Biomarin Pharmaceutical's Book Value per Share for the quarter that ended in Dec. 2023 was $26.26.

During the past 12 months, Biomarin Pharmaceutical's average Book Value per Share Growth Rate was 6.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was 5.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was 10.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was 10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Biomarin Pharmaceutical was 53.30% per year. The lowest was -13.40% per year. And the median was 13.00% per year.


Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical 3-Year Book Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's 3-Year Book Growth Rate falls into.



Biomarin Pharmaceutical 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.


Biomarin Pharmaceutical  (LTS:0HNC) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Biomarin Pharmaceutical 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (LTS:0HNC) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (LTS:0HNC) Headlines

No Headlines